Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Growth in disorders of adrenal hyperfunction.

M O Savage1, S Scommegna, P V Carroll

  • 1Department of Endocrinology, St Bartholomew's and the Royal London School of Medicine and Dentistry, London, UK. m.o.savage@qmul.ac.uk

Hormone Research
|October 10, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tall stature and gigantism in transition age: clinical and genetic aspects-a literature review and recommendations.

Journal of endocrinological investigation·2023
Same author

An international simulated-use study to assess nurses' preferences between two lanreotide syringes for patients with neuroendocrine tumours or acromegaly (PRESTO 3).

Journal of endocrinological investigation·2023
Same author

Sellar and parasellar lesions in the transition age: a retrospective Italian multi-centre study.

Journal of endocrinological investigation·2022
Same author

Renin-angiotensin system inhibitors in management of hypertension during the COVID-19 pandemic.

Journal of physiology and pharmacology : an official journal of the Polish Physiological Society·2020
Same author

Epigenetic pathway inhibitors represent potential drugs for treating pancreatic and bronchial neuroendocrine tumors.

Oncogenesis·2017
Same author

Local optometrists are a major source of referrals to a pituitary tumour clinic.

Endocrine-related cancer·2017
Same journal

Abstracts of the LWPES/ESPE 8th Joint Meeting Global Care in Paediatric Endocrinology, in collaboration with APEG, APPES, JSPE and SLEP. New York City, New York, USA. September 9-12, 2009.

Hormone research·2011
Same journal

Abstracts of the 47th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Istanbul, Turkey. September 20-23, 2008.

Hormone research·2011
Same journal

Abstracts of the 46th Annual Meeting of the European Society for Paediatric Endocrinology (ESPE). Helsinki, Finland. June 27-30, 2007.

Hormone research·2011
Same journal

Genetic and pathogenetic aspects of Noonan syndrome and related disorders.

Hormone research·2009
Same journal

Response to growth hormone in short children with Noonan syndrome: correlation to genotype.

Hormone research·2009
Same journal

Growth hormone and the heart in Noonan syndrome.

Hormone research·2009
See all related articles

Children with Cushing's disease often experience stunted growth and delayed bone age. Treatment with human growth hormone (hGH) after curing Cushing's disease significantly improves long-term growth outcomes.

Area of Science:

  • Pediatric Endocrinology
  • Adrenal Disorders
  • Growth Hormone Therapy

Background:

  • Adrenal hypersecretion of androgens or cortisol disrupts normal growth patterns in children.
  • Cushing's disease (CD) in pediatric patients is associated with subnormal linear growth and delayed bone age.
  • Virilization and altered androgen levels are frequently observed in pediatric CD.

Purpose of the Study:

  • To investigate growth disturbances in pediatric patients with Cushing's disease (CD).
  • To assess growth hormone (GH) status after treatment for CD.
  • To evaluate the efficacy of human growth hormone (hGH) therapy for catch-up growth in these patients.

Main Methods:

  • Studied growth in 19 pediatric patients with CD, assessing height SDS, height velocity, and BMI SDS at diagnosis.

Related Experiment Videos

  • Evaluated GH status in 13 patients post-treatment (transsphenoidal surgery and/or pituitary irradiation) using insulin tolerance test/glucagon.
  • Monitored growth in 10 patients receiving hGH therapy (with or without GnRH analogue) for long-term catch-up growth.

    • Main Results:

    • Pediatric CD patients presented with short stature (mean height SDS -1.81) and elevated BMI SDS.
    • Growth hormone deficiency was common after CD cure, persisting for years in many patients.
    • hGH therapy led to significant long-term catch-up growth, improving height SDS from -1.72 to -0.83.

    Conclusions:

    • Most pediatric patients with Cushing's disease exhibit subnormal linear growth and delayed bone maturation.
    • Growth hormone deficiency is a frequent and persistent complication following treatment for pediatric CD.
    • Human growth hormone therapy is effective in promoting significant long-term catch-up growth, leading to improved final height in children treated for CD.